Salem, Mass. – June 29, 2021 – Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce that two of its cofounders, Craig Strasnick and Gray W. Rifkin, were honored recently amongst their peers in both business and healthcare. Strasnick, CDI President and CEO, was named to the Forbes Next 1000 list of upstart entrepreneurs redefining the American dream. Rifkin, CDI’s COO and CLO, was named one of the Top 100 Healthcare Leaders by the International Forum on Advancements in Healthcare (IFAH).
Strasnick was included in the second installment of 250 entrepreneurs on the Forbes Next 1000, presented by Square, which will spotlight a total of 1,000 entrepreneurs, announced each quarter, in installments of 250 standouts. Candidates are evaluated based on funding, revenue, business model, impact, and personal story.
“I am extremely honored to be included on the 2021 Forbes Next 1000 list alongside a truly inspiring group of ambitious entrepreneurs and small business leaders who are redefining what it means to build and run a business amid the new normal,” said Strasnick.
Rifkin was honored at the IFAH USA Conference at the MGM in Las Vegas in June. IFAH is a global healthcare conference that brings together health and wellness leaders contributing to shaping the future of healthcare delivery. This year’s awardees include some of the brightest minds and organizations globally that have made immense progress in the healthcare industry, particularly with innovative contributions to healthcare delivery during COVID-19.
“I would like to thank IFAH for the honor and recognizing the hard work and dedication of the CDI team to our patient and provider communities. Through diligent planning, agile execution, and focused commitment, CDI maintained its operations throughout the entire COVID-19 pandemic in a safe and compliant manner. As a result, we helped thousands of healthcare providers and tens of thousands of patients maintain continuity of care during a perilous time,” said Rifkin. “We are so proud of that work and would like to recognize not only our internal team but also our industry partners and stakeholders that we work with daily to deliver coordinated care and innovative solutions in GI.
Strasnick continued, “These recognitions belong to our entire team at CDI, who remains steadfast in our mission and only grows stronger every day. Congratulations to all the other Forbes and IFAH honorees, including the countless business leaders from Massachusetts and the healthcare industry overall.”
About Commonwealth Diagnostics International, Inc:
Commonwealth Diagnostics International, Inc. (CDI) is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments. Focused on our patient-centric principles, our cost-effective portfolio of diagnostic products results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Our expansive portfolio includes non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methane Overgrowth (IMO), and carbohydrate malabsorption disorders, as well as IBSchek®, a proprietary capillary collection test for Irritable Bowel Syndrome (IBS-D/M), and MyGiHealth, a cloud-based platform that enables patients to monitor, manage and understand their GI-related symptoms. Operating out of our CLIA-certified laboratory and as an FDA-registered, ISO 13485 certified medical device manufacturer, we pride ourselves on our partnerships with industry-leading health systems, hospitals, and private practices worldwide. For more information, visit commdx.com.
